JP7850670B2 - ギンセノシド組成物 - Google Patents

ギンセノシド組成物

Info

Publication number
JP7850670B2
JP7850670B2 JP2022556000A JP2022556000A JP7850670B2 JP 7850670 B2 JP7850670 B2 JP 7850670B2 JP 2022556000 A JP2022556000 A JP 2022556000A JP 2022556000 A JP2022556000 A JP 2022556000A JP 7850670 B2 JP7850670 B2 JP 7850670B2
Authority
JP
Japan
Prior art keywords
weight
approximately
ginsenosides
composition
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022556000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023519189A5 (https=
JPWO2021185890A5 (https=
JP2023519189A (ja
Inventor
レコザネット，ロマーン
エリザベット レネー ファンカ－ベルトン，パスカル
Original Assignee
ジボダン エス エー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2004121.6A external-priority patent/GB202004121D0/en
Priority claimed from GBGB2005288.2A external-priority patent/GB202005288D0/en
Application filed by ジボダン エス エー filed Critical ジボダン エス エー
Publication of JP2023519189A publication Critical patent/JP2023519189A/ja
Publication of JP2023519189A5 publication Critical patent/JP2023519189A5/ja
Publication of JPWO2021185890A5 publication Critical patent/JPWO2021185890A5/ja
Application granted granted Critical
Publication of JP7850670B2 publication Critical patent/JP7850670B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
JP2022556000A 2020-03-20 2021-03-17 ギンセノシド組成物 Active JP7850670B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2004121.6A GB202004121D0 (en) 2020-03-20 2020-03-20 Improved compositions
GB2004121.6 2020-03-20
GBGB2005288.2A GB202005288D0 (en) 2020-04-09 2020-04-09 Improved compositions
GB2005288.2 2020-04-09
PCT/EP2021/056788 WO2021185890A1 (en) 2020-03-20 2021-03-17 Ginsenoside compositions

Publications (4)

Publication Number Publication Date
JP2023519189A JP2023519189A (ja) 2023-05-10
JP2023519189A5 JP2023519189A5 (https=) 2024-03-27
JPWO2021185890A5 JPWO2021185890A5 (https=) 2024-03-27
JP7850670B2 true JP7850670B2 (ja) 2026-04-23

Family

ID=75108332

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022556000A Active JP7850670B2 (ja) 2020-03-20 2021-03-17 ギンセノシド組成物
JP2022555990A Active JP7808042B2 (ja) 2020-03-20 2021-03-17 ギンセノシド組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022555990A Active JP7808042B2 (ja) 2020-03-20 2021-03-17 ギンセノシド組成物

Country Status (8)

Country Link
US (2) US20230124503A1 (https=)
EP (2) EP4121061A1 (https=)
JP (2) JP7850670B2 (https=)
CN (2) CN115315266A (https=)
AU (2) AU2021238639A1 (https=)
BR (2) BR112022015826A2 (https=)
CA (2) CA3174699A1 (https=)
WO (2) WO2021185890A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021185890A1 (en) * 2020-03-20 2021-09-23 Givaudan Sa Ginsenoside compositions
CN117224553B (zh) * 2023-11-02 2025-08-12 浙江大学 人参皂苷Rg3在制备治疗或预防肠道病毒感染的药物中的应用
CN117752706B (zh) * 2023-12-20 2025-10-14 浙江天皇药业有限公司 西洋参炮制品在制备治疗甲状腺功能减退症药物中的应用
WO2025261873A1 (en) 2024-06-20 2025-12-26 Givaudan Sa Improvements in or relating to compounds

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278944A1 (en) 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
WO2019016731A1 (en) 2017-07-18 2019-01-24 Senescence Life Sciences Pte. Ltd. COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF COGNITIVE DECLINE AND PRESERVATION OF NEURONAL FUNCTIONS
CN110613802A (zh) 2018-06-20 2019-12-27 珠海岐微生物科技有限公司 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途
JP2023518064A (ja) 2020-03-20 2023-04-27 ジボダン エス エー ギンセノシド組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202731A1 (en) * 2003-04-08 2004-10-14 Gow Robert T. Rosmarinic acid composition
US9956241B2 (en) * 2009-05-04 2018-05-01 Naturex, S.A. Application of American Ginseng to enhance neurocognitive function
US10456436B2 (en) * 2013-11-04 2019-10-29 Wen Luan Wendy Hsiao Use of herbal saponins to regulate gut microflora
CN109432304A (zh) * 2018-12-03 2019-03-08 杭州胡庆余堂药业有限公司 一种含铁皮石斛组合物在药物制备中的应用

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100278944A1 (en) 2009-05-04 2010-11-04 Naturex, S.A. Application of american ginseng to enhance neurocognitive function
WO2019016731A1 (en) 2017-07-18 2019-01-24 Senescence Life Sciences Pte. Ltd. COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF COGNITIVE DECLINE AND PRESERVATION OF NEURONAL FUNCTIONS
CN110613802A (zh) 2018-06-20 2019-12-27 珠海岐微生物科技有限公司 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途
JP2023518064A (ja) 2020-03-20 2023-04-27 ジボダン エス エー ギンセノシド組成物

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Andrew Scholey, et al.，Effects of American ginseng (Panax quinquefolius) on neurocognitive function: an acute, randomised, double-blind, placebo-controlled, crossover study，Psychopharmacology，2010年，Vol.212，pp.345-356，DOI 10.1007/s00213-010-1964-y
Cesare Mancuso, et al.，Panax ginseng and Panax quinquefolius: From pharmacology to toxicology，Food and Chemical Toxicology，2017年，Vol.107，pp.362-372
Debra L. Barton, et al.，Wisconsin Ginseng (Panax quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind Trial, N07C2，Journal of the National Cancer Institute，2013, ，Vol.105, No.16，pp.1230-1238，DOI:10.1093/jnci/djt181
J. Ginseng Res.，2007年，Vol.31, No.1，pp.34-43
U.S. National Library of Medicine，Investigating the Acute and Chronic Effects of an American Ginseng Root Extract on Cognition and Mood，ClinicalTrials.gov，NCT03579095，[retrieved on 2024.12.14]，2019年，retrieved from internet:，<URL: https://clinicaltrials.gov/study/NCT03579095?a=2>

Also Published As

Publication number Publication date
CA3174698A1 (en) 2021-09-23
US20230129389A1 (en) 2023-04-27
CN115315264A (zh) 2022-11-08
JP7808042B2 (ja) 2026-01-28
BR112022016241A2 (pt) 2022-10-11
US20230124503A1 (en) 2023-04-20
AU2021238639A1 (en) 2022-09-15
BR112022015826A2 (pt) 2022-10-04
EP4121061A1 (en) 2023-01-25
EP4121076A1 (en) 2023-01-25
WO2021185890A1 (en) 2021-09-23
AU2021238643A1 (en) 2022-10-20
JP2023518064A (ja) 2023-04-27
WO2021185897A1 (en) 2021-09-23
JP2023519189A (ja) 2023-05-10
CA3174699A1 (en) 2021-09-23
CN115315266A (zh) 2022-11-08

Similar Documents

Publication Publication Date Title
JP7850670B2 (ja) ギンセノシド組成物
Limanaqi et al. Potential antidepressant effects of Scutellaria baicalensis, Hericium erinaceus and Rhodiola rosea
Liu et al. Polymannuronic acid prebiotic plus Lacticaseibacillus rhamnosus GG probiotic as a novel synbiotic promoted their separate neuroprotection against Parkinson’s disease
Qu et al. Impact of traditional Chinese medicine treatment on chronic unpredictable mild stress-induced depression-like behaviors: intestinal microbiota and gut microbiome function
Chen et al. Dietary saponins from four popular herbal tea exert prebiotic-like effects on gut microbiota in C57BL/6 mice
Lv et al. Forsythia suspensa polyphenols regulate macrophage M1 polarization to alleviate intestinal inflammation in mice
Li Treatment of asthma and food allergy with herbal interventions from traditional Chinese medicine
Liu et al. Microbiome and metabolome integrally reveal the anti-depression effects of Cistanche deserticola polysaccharides from the perspective of gut homeostasis
Cao et al. P-coumaric acid ameliorates Aβ25–35-induced brain damage in mice by modulating gut microbiota and serum metabolites
US20110165273A1 (en) A composition of extracts from plants and the use thereof in prophylaxis or treatment of metabolism disorder of blood lipid
CN102233009B (zh) 一种促进神经再生的中药组合物及其制备方法和应用
JP7693243B2 (ja) 認知機能改善剤
Xu et al. Study on the anti-Parkinson's disease activity mechanism and preparation of panaxadiol
Zhang et al. Dendrobium nobile Lindl ameliorates learning and memory deficits in scopolamine-treated mice
CN108785370A (zh) 一种用于治疗高血脂症及动脉粥样硬化的药物组合物
Xu et al. Water extract of ginseng alleviates Parkinsonism in MPTP–induced Parkinson’s disease mice
Lan et al. Protective mechanisms of Hovenia dulcis Thunb extracts on acute alcoholism and liver injury
US11707497B2 (en) Methods and compositions with purified Bombyx mori cocoon silk peptide fiber and refined Buglossoides arvensis seed oil providing anti-inflammatory effects and neuroprotection for disease states
TW201636036A (zh) 用於預防改善或治療身心俱疲症候群之組合物
Li et al. Hemp seed oil ameliorates CFA-induced rheumatoid arthritis in rats by improving metabolic abnormalities and gut microflora
Lee et al. Effect of a Salvia officinalis and Hypericum perforatum mixture on improving memory and cognitive decline
Ji et al. Exploring the effect of Kaixin San on Alzheimer's disease by regulating the Keap1/Nrf2/GPX4 signaling pathway to inhibit ferroptosis based on metabolomics and gut microbiota analysis
Chi Study on biofate and antidepressive mechanism of fructooligosaccharides from Morinda officinalis
Islam et al. An Evaluation of Pharmacological Healing Potentialities of Phyllanthus Emblica and Terminalia Chebula on Experimental Rat Models
CN110613802A (zh) 白茅根大黄炭三七组合物及其在调节肠道微生物中的用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240314

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20240314

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20241217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241219

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250901

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260122

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260408

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260413